Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

28,000

Employees28,000

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

28,000

Employees28,000

AMGN Key Statistics

Market cap

149.24B

Market cap149.24B

Price-Earnings ratio

23.13

Price-Earnings ratio23.13

Dividend yield

3.32%

Dividend yield3.32%

Average volume

2.12M

Average volume2.12M

High today

$283.31

High today$283.31

Low today

$276.88

Low today$276.88

Open price

$281.04

Open price$281.04

Volume

989.53K

Volume989.53K

52 Week high

$339.17

52 Week high$339.17

52 Week low

$253.30

52 Week low$253.30

AMGN News

Simply Wall St 2d

Amgen And Kyowa Kirin Reveal Initial Results From Rocatinlimab ASCEND Study

and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new therapy for atopic dermatitis, which could potentia...

Benzinga 3d

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. AMGN and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to se...

TipRanks 3d

Amgen, Kyowa Kirin announce preliminary results from ASCEND study

Amgen (AMGN) and Kyowa Kirin announced preliminary top-line results from the ASCEND study evaluating rocatinlimab, an investigational T-cell rebalancing therapy...

Analyst ratings

47%

of 34 ratings

Buy

44.1%

Hold

47.1%

Sell

8.8%

More AMGN News

Simply Wall St 4d

A Look at Amgen’s Valuation Following FDA Nod Expanding Repatha’s Patient Reach

Amgen (AMGN) just received expanded FDA approval for its cholesterol-lowering drug, Repatha, allowing doctors to prescribe it to an even broader pool of adults...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.